A SHR0302 BA Study on Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions

Autoimmune Diseases

Interventions

DRUG

SHR0302 quick release tablets

SHR0302 quick release tablets 8 mg

DRUG

SHR0302 sustained-release tablets

SHR0302 sustained-release tablets 10 mg

Trial Locations (1)

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06202612 - A SHR0302 BA Study on Healthy Subjects | Biotech Hunter | Biotech Hunter